Abstract
British Journal of DermatologyVolume 154, Issue 5 p. 1000-1002 Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy J. Tillon, J. Tillon Departments of Internal MedicineSearch for more papers by this authorF. Hervé, F. Hervé Departments of Internal MedicineSearch for more papers by this authorD. Chevallier, D. Chevallier Departments of Internal MedicineSearch for more papers by this authorJ-F. Muir, J-F. Muir PneumologySearch for more papers by this authorH. Levesque, H. Levesque Departments of Internal MedicineSearch for more papers by this authorI. Marie, I. Marie Departments of Internal Medicine PneumologySearch for more papers by this author J. Tillon, J. Tillon Departments of Internal MedicineSearch for more papers by this authorF. Hervé, F. Hervé Departments of Internal MedicineSearch for more papers by this authorD. Chevallier, D. Chevallier Departments of Internal MedicineSearch for more papers by this authorJ-F. Muir, J-F. Muir PneumologySearch for more papers by this authorH. Levesque, H. Levesque Departments of Internal MedicineSearch for more papers by this authorI. Marie, I. Marie Departments of Internal Medicine PneumologySearch for more papers by this author First published: 14 March 2006 https://doi.org/10.1111/j.1365-2133.2006.07194.xCitations: 24 Isabelle Marie. E-mail: isabelle.marie@chu-rouen.fr Conflicts of interest: none declared. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume154, Issue5May 2006Pages 1000-1002 RelatedInformation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.